Loading organizations...

Ducentis BioTherapeutics is a technology company.
Ducentis BioTherapeutics developed novel therapies for inflammation and autoimmune diseases via checkpoint agonism. Its lead candidate, DS-234, is a fusion protein designed to selectively agonize the CD200 receptor. This mechanism aims to restore immune homeostasis by inducing inhibitory signaling on immune cells that regulate inflammation, pioneering treatments modulating the CD200 pathway to address overactive immune responses.
Ducentis BioTherapeutics was founded in 2015 by Dr. Philip Huxley, Professor David Blackbourn, and Dr. Rebecca Ashfield. Their founding insight was the significant potential of the CD200 pathway to control exaggerated immune responses, which guided the development of therapies precisely targeting immune dysregulation.
The company initially focused on atopic dermatitis, identifying it as a lead indication with substantial unmet patient needs. Ducentis BioTherapeutics aimed to offer a differentiated therapeutic approach for autoimmune conditions, moving beyond conventional blockade mechanisms to restore immune balance. Their vision centered on developing innovative solutions for diseases lacking effective treatments, thereby improving patient outcomes.
Ducentis BioTherapeutics has raised $2.0M across 2 funding rounds.
Ducentis BioTherapeutics has raised $2.0M in total across 2 funding rounds.
Ducentis BioTherapeutics Ltd. is a preclinical-stage biotechnology company focused on developing novel fusion protein therapies targeting the CD200 receptor (CD200R) pathway to treat inflammation and autoimmune diseases, particularly atopic dermatitis.[1][2][3] Its lead asset, DS-234, is a highly selective and potent CD200R agonist designed to restore immune homeostasis by inhibiting over-active immune responses via checkpoint agonism, addressing unmet needs in underserved markets like atopic dermatitis.[1][2][6] The company served patients with autoimmune conditions lacking effective options and demonstrated strong growth momentum through its 2022 acquisition by Arcutis Biotherapeutics (Nasdaq: ARQT) for up to $400 million, validating its science and enabling accelerated clinical development under Arcutis' immuno-dermatology expertise.[2][3][5]
Founded in 2015 by Dr. Philip Huxley (Founder and former CEO), Professor David Blackbourn, and Dr. Rebecca Ashfield, Ducentis emerged from the idea of harnessing the CD200 pathway to control exaggerated immune responses in autoimmune diseases.[1][2] Incorporated on November 17, 2014, in the UK (initially as Deucentis Limited, with early name changes), the company built early traction through backing from LifeArc Ventures, its largest investor, which supported translational research on DS-234.[2][3][4] A pivotal moment came in September 2022 when Arcutis acquired it, with Huxley noting Arcutis' resources would advance DS-234 from preclinical stages toward proof-of-concept in atopic dermatitis and beyond.[1][3]
Ducentis rode the wave of immunomodulatory biologics and checkpoint therapies, extending cancer immunotherapy concepts (e.g., PD-1 inhibitors) to autoimmune diseases by activating tolerance pathways like CD200R amid rising atopic dermatitis prevalence.[1][2] Timing aligned with a booming immuno-dermatology market—underserved and rapidly growing—fueled by demand for non-steroidal, targeted options beyond JAK inhibitors or biologics like dupilumab.[2][3] Market forces favoring it included investor appetite for de-risked preclinical assets (e.g., validated targets) and M&A activity, as seen in its acquisition by Arcutis, which influences the ecosystem by accelerating novel assets into clinical pipelines and validating UK biotech innovation.[1][5][7]
Post-acquisition, DS-234 advances under Arcutis toward proof-of-concept trials in atopic dermatitis, with potential expansion to other autoimmune diseases, leveraging Arcutis' manufacturing and commercial biologics experience.[1][3] Trends like precision immunomodulation and biologics dominance in dermatology will shape its path, potentially evolving checkpoint agonism into a new standard if data succeeds. Ducentis' swift $400M exit underscores its foundational promise, now amplified by Arcutis to deliver transformative therapies from a validated immune checkpoint.[2][3]
Ducentis BioTherapeutics has raised $2.0M in total across 2 funding rounds.
Ducentis BioTherapeutics's investors include David Holbrook, Oxford Technology Management.
Ducentis BioTherapeutics has raised $2.0M across 2 funding rounds. Most recently, it raised $1.9M Seed in June 2019.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Jun 14, 2019 | $1.9M Seed | David Holbrook | |
| Dec 1, 2015 | $120K Seed | Oxford Technology Management |